Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure
Article 2013 en
Authors
KS
Karl Swedberg
JY
James B. Young
IA
Inder S. Anand
Abstract
1 min read
Treatment with darbepoetin alfa did not improve clinical outcomes in patients with systolic heart failure and mild-to-moderate anemia. Our findings do not support the use of darbepoetin alfa in these patients. (Funded by Amgen; RED-HF ClinicalTrials.gov number, NCT00358215.).
John J.V. McMurray, Inder S. Anand, Rafael Díaz, Aldo Maggioni, Christopher M. O’Connor, Marc A. Pfeffer, Scott D. Solomon, Michał Tendera, Dirk J. van Veldhuisen, Moetaz Albizem, Sunfa Cheng, Debra Scarlata, Karl Swedberg, James B. Young
Akshay S. Desai, Henry Krum, Changhong Yu, Scott M. Wasserman, Eduard Apetrei, Vijay Chopra, Mareev VIu, Aldo Maggioni, John J.V. McMurray, Marc A. Pfeffer, Karl Swedberg, James B. Young
Marc A. Pfeffer, Emmanuel A. Burdmann, Chao Yin Chen, Mark E. Cooper, Dick de Zeeuw, Kai-Uwe Eckardt, Jan Feyzi, Peter Ivanovich, Reshma Kewalramani, Andrew S. Levey, Eldrin F. Lewis, Janet B. McGill, John J.V. McMurray, Patrick S. Parfrey, Hans Henrik Parving, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto
Paul Welsh, Changhong Yu, John J.V. McMurray, Inder S. Anand, Naveed Sattar, Dirk J. van Veldhuisen, Lars Gullestad, Aldo Maggioni, Akshay S. Desai, Scott D. Solomon, Sunfa Cheng, Marc A. Pfeffer, Lei Kou, Karl Swedberg, James B. Young
John J.V. McMurray, Inder S. Anand, Rafael Díaz, Aldo Maggioni, Christopher M. O’Connor, Marc A. Pfeffer, Rajamani Krishna, Scott D. Solomon, Yan Sun, Karl Swedberg, Michał Tendera, Dirk J. van Veldhuisen, Scott M. Wasserman, James B. Young
Discussion(0)
No comments yet. Be the first to comment.